Oligoprogressive Non-Small-Cell Lung Cancer under Treatment with PD-(L)1 Inhibitors

Oligoprogression (OPD) of non-small-cell lung cancer (NSCLC) occurs in approximately half of patients under targeted compounds (TKI) and facilitates use of regional therapies that can prolong survival. In order to characterize OPD in immunotherapy (IO)-treated NSCLC, we analyzed the failure pattern under PD-1/PD-L1 inhibitors (n = 297) or chemoimmunotherapy (n = 75). Under IO monotherapy, OPD was more frequent (20% vs. 10%, p < 0.05), occurred later (median 11 vs. 5 months, p < 0.01), affected fewer sites (mean 1.1 vs. 1.5, p < 0.05), and involved fewer lesions (1.4 vs. 2.3, p < 0.05) in the first compared to later lines. Lymph nodes (42%, mainly mediastinal) and the brain (39%) were mostly affected, followed by the lung (24%) and other organs. Compared to multifocal progression, OPD occurred later (11 vs. 4 months, p < 0.001) and was associated with longer survival (26 vs. 13 months, p < 0.001) and higher tumor PD-L1 expression (p < 0.001). Chemoimmunotherapy showed a similar incidence of OPD as IO monotherapy (13% vs. 11% at 2 years). Local treatments were applied regularly for brain but only in 50% for extracranial lesions. Thus, NSCLC oligoprogression is less common under IO than under TKI, but also favorable. Since its frequency drops later in the disease, regular restaging and multidisciplinary evaluation are essential in order to exploit the full therapeutic potential.

[1]  J. Lunceford,et al.  KRAS mutational status and efficacy in KEYNOTE-189: Pembrolizumab (pembro) plus chemotherapy (chemo) vs placebo plus chemo as first-line therapy for metastatic non-squamous NSCLC , 2019 .

[2]  J. Thariat,et al.  Stereotactic ablative radiotherapy and systemic treatments for extracerebral oligometastases, oligorecurrence, oligopersistence and oligoprogression from lung cancer , 2019, BMC Cancer.

[3]  D. Palma,et al.  The Dandelion Dilemma Revisited for Oligoprogression: Treat the Whole Lawn or Weed Selectively? , 2019, Clinical oncology (Royal College of Radiologists (Great Britain)).

[4]  J. Lunceford,et al.  LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042 , 2019 .

[5]  J. Lunceford,et al.  Association between tissue TMB (tTMB) and clinical outcomes with pembrolizumab monotherapy (pembro) in PD-L1-positive advanced NSCLC in the KEYNOTE-010 and -042 trials , 2019, Annals of Oncology.

[6]  N. Bartolomeo,et al.  The Management of Oligoprogression in the Landscape of New Therapies for Metastatic Melanoma , 2019, Cancers.

[7]  J. Lunceford,et al.  Pembrolizumab (pembro) plus platinum-based chemotherapy (chemo) for metastatic NSCLC: Tissue TMB (tTMB) and outcomes in KEYNOTE-021, 189, and 407 , 2019, Annals of Oncology.

[8]  Yuqing Wei,et al.  Prognostic role of pretreatment neutrophil-to-lymphocyte ratio in non-small cell lung cancer patients treated with systemic therapy: a meta-analysis. , 2019, Translational lung cancer research.

[9]  A. Stenzinger,et al.  Defining molecular risk in ALK+ NSCLC , 2019, Oncotarget.

[10]  C. Britschgi,et al.  Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. , 2019, Lung cancer.

[11]  D. Reardon,et al.  Efficacy and safety of immune checkpoint blockade for brain metastases , 2019, CNS oncology.

[12]  A. Tafreshi,et al.  Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  P. Schirmacher,et al.  Detection of TP53 Mutations in Tissue or Liquid Rebiopsies at Progression Identifies ALK+ Lung Cancer Patients with Poor Survival , 2019, Cancers.

[14]  Qinghua Xu,et al.  First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease , 2019, Journal of Cancer.

[15]  S. Leroy,et al.  Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors. , 2019, Journal of thoracic disease.

[16]  A. Stenzinger,et al.  Clinical and laboratory predictors of immune checkpoint inhibitor efficacy in non-small cell lung cancer , 2018, Annals of Oncology.

[17]  C. Gridelli,et al.  Brigatinib versus Crizotinib in ALK‐Positive Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[18]  S. Leschka,et al.  Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC) , 2018, Cancer Immunology, Immunotherapy.

[19]  K. Syrigos,et al.  Sarcoidosis‐Like Reactions Induced by Checkpoint Inhibitors , 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  P. Iyengar,et al.  The current state of oligometastatic and oligoprogressive non-small cell lung cancer. , 2018, Journal of thoracic disease.

[21]  Michael Thomas,et al.  Large cell neuroendocrine lung carcinoma induces peripheral T-cell repertoire alterations with predictive and prognostic significance. , 2018, Lung cancer.

[22]  S. Novello,et al.  Pembrolizumab plus Chemotherapy in Metastatic Non–Small‐Cell Lung Cancer , 2018, The New England journal of medicine.

[23]  S. Bonin,et al.  Overview on Clinical Relevance of Intra-Tumor Heterogeneity , 2018, Front. Med..

[24]  J. Wargo,et al.  Granulomatous/sarcoid-like lesions associated with checkpoint inhibitors: a marker of therapy response in a subset of melanoma patients , 2018, Journal of Immunotherapy for Cancer.

[25]  D. Camidge,et al.  Reviewing RECIST in the Era of Prolonged and Targeted Therapy. , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[26]  Laurence Zitvogel,et al.  The immune contexture in cancer prognosis and treatment , 2017, Nature Reviews Clinical Oncology.

[27]  Rafal Dziadziuszko,et al.  Alectinib versus Crizotinib in Untreated ALK‐Positive Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[28]  J. Taube,et al.  Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC , 2017, Cancer Immunology Research.

[29]  Chuong D. Hoang,et al.  Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[30]  Lauren L. Ritterhouse,et al.  Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer , 2016 .

[31]  Ping Yang,et al.  Prognostic effect of liver metastasis in lung cancer patients with distant metastasis , 2016, Oncotarget.

[32]  Umberto Ricardi,et al.  An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. , 2014, Clinical lung cancer.

[33]  R. Doebele,et al.  Clinical Investigation : Thoracic Cancer Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib , 2014 .

[34]  C. Sima,et al.  Local Therapy with Continued EGFR Tyrosine Kinase Inhibitor Therapy as a Treatment Strategy in EGFR-Mutant Advanced Lung Cancers That Have Developed Acquired Resistance to EGFR Tyrosine Kinase Inhibitors , 2013, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[35]  P. Bunn,et al.  Local Ablative Therapy of Oligoprogressive Disease Prolongs Disease Control by Tyrosine Kinase Inhibitors in Oncogene-Addicted Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[36]  Yukiko Nakamura,et al.  Continuous EGFR-TKI administration following radiotherapy for non-small cell lung cancer patients with isolated CNS failure. , 2011, Lung cancer.

[37]  A. Nagrial,et al.  P3.02c-033 Patterns of Progression and Management of Acquired Resistance to Anti-PD-1 Antibodies in Advanced Non-Small Cell Lung Cancer: Topic: IT , 2017 .

[38]  R. Herbst,et al.  Programmed death ligand-1 expression in non-small cell lung cancer , 2014, Laboratory Investigation.

[39]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.